Maelstrom Research Staging | VIP_autoSCT_180_days_postdose

VIP_autoSCT_180_days_postdose_2

Networks -

Variables -

Population

VIP - autoSCT patients

The population is composed of hematologic malignancy patients who received an autologous hematopoietic stem cell transplant (autoSCT), aged 18 years and older, who intend to receive the COVID-19 vaccine or have received the COVID-19 vaccine at any time in the past.

Selection Criteria

Minimum age

Newborns

Twins

Countries

Canada

Territory

Edmonton, Montreal, Ottawa, Toronto

Ethnic Origin

Health Status

Participants are diagnosed with hematologic malignancy.

Participants are excluded if they have chronic myelogenous leukemia, myeloproliferative neoplasm not on cytoreductive therapy, or any absolute contraindications to the COVID-19 vaccine.

Other Criteria

Participants are included if it has been at least 3 months since they have received an autologous hematopoietic stem cell transplant from the time of enrollment.

Participants are excluded if they received an autologous stem cell transplantation (autoSCT) or allogeneic hematopoietic stem cell transplantation (alloSCT) treatment for non-hematologic malignancy diseases.

Recruitment

Sources of recruitment

Specific population

Specific Population

Clinic patients

Supplementary Information

Participants are recruited in hematology clinics from one of twelve participating hospitals around Canada.

Number of Participants

Number of Participants: 162
Number of Participants with Biological Samples: 162

More info

Data Collection Event

VIP - autoSCT patients - Follow-up 180 days post-dose 2

Information is collected about potential COVID-19 exposures, COVID-19 infections, and changes in medical history. Blood samples are collected.

More info

Collected Dataset / VIP_autoSCT_180_days_postdose_2

VIP_autoSCT_180_days_postdose_2

Population

VIP - autoSCT patients

Data Collection Event

VIP - autoSCT patients - Follow-up 180 days post-dose 2

Files

Variables Classifications